Table 4_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…</p>Conclusion<p>This study illustrates the global progress made in reducing neonatal encephalopathy from 1990 to 2021; however, significant disparities persist. …”

Image 1_PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients.pdf by Ana Virseda-Berdices (9638081)

“…Background<p>HCV eradication with antiviral treatment reduces hepatic disease, but some patients remain at risk of progression to cirrhosis despite HCV clearance. We aimed to examine the association between peripheral blood mononuclear cells (PBMCs) gene expression before HCV therapy and a pronounced decrease in the liver stiffness measurement (LSM) value in HIV/HCV-coinfected patients after HCV treatment and achievement of sustained virological response (SVR).…”

Table 3_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…</p>Conclusion<p>This study illustrates the global progress made in reducing neonatal encephalopathy from 1990 to 2021; however, significant disparities persist. …”

Data Sheet 1_The disproportionate burden of pulmonary arterial hypertension among the elderly: global, regional, and national trends from 1990 to 2021—findings from the 2021 global... by Meng Tang (139012)

“…BAPC projections suggest a potential decrease in the global PAH burden by 2035.</p>Conclusions<p>Progress in reducing the PAH disease burden during 1990–2021 was limited globally, nationally, and regionally. …”

Data Sheet 1_Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-in... by Zhixue Fu (7540256)

“…Overall survival (OS), progression-free survival (PFS), recurrence pattern, and safety were evaluated.…”

Image 4_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Table 6_Global burden of low back pain attributable to smoking in 204 countries and territories in 1990–2021.xlsx by Baodong Wang (3359171)

“…Finally, it is forecasted that the smoking-related LBP burden will decrease from 2022 to 2036.</p>Conclusion<p>From 1990 to 2021, the global ASDR of LBP attributable to smoking decreased, and this downward trend is expected to persist. …”

Table 4_Global burden of low back pain attributable to smoking in 204 countries and territories in 1990–2021.xlsx by Baodong Wang (3359171)

“…Finally, it is forecasted that the smoking-related LBP burden will decrease from 2022 to 2036.</p>Conclusion<p>From 1990 to 2021, the global ASDR of LBP attributable to smoking decreased, and this downward trend is expected to persist. …”

Image 2_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Table 5_Global burden of low back pain attributable to smoking in 204 countries and territories in 1990–2021.xlsx by Baodong Wang (3359171)

“…Finally, it is forecasted that the smoking-related LBP burden will decrease from 2022 to 2036.</p>Conclusion<p>From 1990 to 2021, the global ASDR of LBP attributable to smoking decreased, and this downward trend is expected to persist. …”

Opposing mechanisms by which miRNAs mediate distinct Nrf1 and Nrf2 regulation of epithelial–mesenchymal transition in hepatocellular carcinoma by Juan Chen (61123)

“…The <i>Nrf1α</i>^{<i>–/–</i>}-leading EMT results from a significant decrease in the epithelial CDH1 expression, plus another increased expression of the mesenchymal CDH2. …”

Table 1_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Data of Fig 5C. by Xianyu Piao (145967)

“…Hepatic schistosomulum treated with SjCL1 antibodies <i>in vitro</i> showed significant growth retardation, although remained viable and developed intestinal heme pigmentation, indicative of hemoglobin digestion.…”

Table 3_Global burden of low back pain attributable to smoking in 204 countries and territories in 1990–2021.xlsx by Baodong Wang (3359171)

“…Finally, it is forecasted that the smoking-related LBP burden will decrease from 2022 to 2036.</p>Conclusion<p>From 1990 to 2021, the global ASDR of LBP attributable to smoking decreased, and this downward trend is expected to persist. …”

Video 1_Real-time segmentation and phenotypic analysis of rice seeds using YOLOv11-LA and RiceLCNN.mp4 by Dejia Zhang (18526510)

“…These modifications not only improve detection accuracy but also significantly reduce the number of parameters by 63.2% and decrease computational complexity by 51.6%. …”

Image 3_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Table 7_Global burden of low back pain attributable to smoking in 204 countries and territories in 1990–2021.xlsx by Baodong Wang (3359171)

“…Finally, it is forecasted that the smoking-related LBP burden will decrease from 2022 to 2036.</p>Conclusion<p>From 1990 to 2021, the global ASDR of LBP attributable to smoking decreased, and this downward trend is expected to persist. …”

Data of Fig 4A. by Xianyu Piao (145967)

“…Hepatic schistosomulum treated with SjCL1 antibodies <i>in vitro</i> showed significant growth retardation, although remained viable and developed intestinal heme pigmentation, indicative of hemoglobin digestion.…”

Table 2_Global burden of low back pain attributable to smoking in 204 countries and territories in 1990–2021.xls by Baodong Wang (3359171)

“…Finally, it is forecasted that the smoking-related LBP burden will decrease from 2022 to 2036.</p>Conclusion<p>From 1990 to 2021, the global ASDR of LBP attributable to smoking decreased, and this downward trend is expected to persist. …”

Image 1_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”